Literature DB >> 18269457

Expression of two isozymes of acyl-coenzyme A: cholesterol acyltransferase-1 and -2 in clear cell type renal cell carcinoma.

Kenshi Matsumoto1, Yukio Fujiwara, Ryoji Nagai, Masaki Yoshida, Shoichi Ueda.   

Abstract

OBJECTIVES: The present study investigated the expression of acyl-coenzyme A: cholesterol acyltransferase-1 (ACAT-1) and -2 in clear cell type renal cell carcinoma (RCC).
METHODS: Clear cell type RCC and corresponding normal kidney tissue samples were obtained from 19 surgical cases (28-85 years of age). Tissue extracts were assayed for ACAT activity and protein expression by immunoblotting with anti-ACAT-1 and anti-ACAT-2 antibodies. Frozen sections were subjected to Oil red O staining for lipids, and were immunostained with ACAT-specific antibodies.
RESULTS: Acyl-coenzyme A cholesterol acyltransferase activity was 5.7-fold higher (P < 0.01) in clear cell carcinoma (23.52 +/- 4.90 pmol/mg protein/min) than in normal kidney (4.12 +/- 0.36). Consistent with this, immunoblotting and immunohistochemical staining revealed strong expression of ACAT-1 in clear cell type RCC. Densitometric analysis showed that ACAT-1 expression was 2.9-fold higher in clear cell type RCC than in normal kidney. In contrast, ACAT-2 expression was negative in clear cell type RCC and normal kidney. Oil red O staining showed massive deposits of lipid in RCC cells.
CONCLUSIONS: We identified strong expression of ACAT-1 in clear cell type RCC. Upregulation of ACAT-1 leads to high ACAT enzymatic activity, which accelerates the accumulation of cholesterol ester in clear cell type RCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18269457     DOI: 10.1111/j.1442-2042.2007.01947.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  10 in total

1.  Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.

Authors:  Jehonathan H Pinthus; Kaitlyn F Whelan; Daniel Gallino; Jian-Ping Lu; Nathan Rothschild
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

2.  Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion.

Authors:  Michael R Paillasse; Philippe de Medina; Guillaume Amouroux; Loubna Mhamdi; Marc Poirot; Sandrine Silvente-Poirot
Journal:  J Lipid Res       Date:  2009-06-05       Impact factor: 5.922

Review 3.  Targeting immune cell metabolism in kidney diseases.

Authors:  Paulo José Basso; Vinicius Andrade-Oliveira; Niels Olsen Saraiva Câmara
Journal:  Nat Rev Nephrol       Date:  2021-04-07       Impact factor: 28.314

4.  Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation.

Authors:  Catharina Bartmann; Sudha R Janaki Raman; Jessica Flöter; Almut Schulze; Katrin Bahlke; Jana Willingstorfer; Maria Strunz; Achim Wöckel; Rainer J Klement; Michaela Kapp; Cholpon S Djuzenova; Christoph Otto; Ulrike Kämmerer
Journal:  Cancer Metab       Date:  2018-06-11

5.  Insulin promotes progression of colon cancer by upregulation of ACAT1.

Authors:  Xin Chen; Huiling Liang; Qibin Song; Ximing Xu; Dedong Cao
Journal:  Lipids Health Dis       Date:  2018-05-24       Impact factor: 3.876

6.  Synergy of Dendritic Cell Vaccines and Avasimibe in Treatment of Head and Neck Cancer in Mice.

Authors:  Xin Chen; Qibin Song; Leiming Xia; Ximing Xu
Journal:  Med Sci Monit       Date:  2017-09-17

7.  Role of Neutral Sphingomyelinase-2 (NSM 2) in the Control of T Cell Plasma Membrane Lipid Composition and Cholesterol Homeostasis.

Authors:  Charlene Börtlein; Fabian Schumacher; Burkhard Kleuser; Lars Dölken; Elita Avota
Journal:  Front Cell Dev Biol       Date:  2019-10-15

8.  AUP1 regulates lipid metabolism and induces lipid accumulation to accelerate the progression of renal clear cell carcinoma.

Authors:  Chen Chen; Wei Zhao; Xingxing Lu; Yunbo Ma; Peizhi Zhang; Zicheng Wang; Zilian Cui; Qinghua Xia
Journal:  Cancer Sci       Date:  2022-06-27       Impact factor: 6.518

9.  Molecular signature of renal cell carcinoma by means of a multiplatform metabolomics analysis.

Authors:  Marta Kordalewska; Renata Wawrzyniak; Julia Jacyna; Joanna Godzień; Ángeles López Gonzálves; Joanna Raczak-Gutknecht; Marcin Markuszewski; Piotr Gutknecht; Marcin Matuszewski; Janusz Siebert; Coral Barbas; Michał J Markuszewski
Journal:  Biochem Biophys Rep       Date:  2022-08-04

10.  Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapy.

Authors:  Hiromu Yano; Yukio Fujiwara; Hasita Horlad; Chang Pan; Keitaro Kai; Daisuke Niino; Kumiko Ohsawa; Morihiro Higashi; Kisato Nosaka; Yutaka Okuno; Jun-Ichi Tamaru; Akitake Mukasa; Masao Matsuoka; Yoshihiro Komohara
Journal:  Cancer Sci       Date:  2022-04-08       Impact factor: 6.518

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.